Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Canonical transient receptor potential channel 3 (TRPC3) is a member of the canonical TRP subfamily of ion channels, notable for forming calcium-permeable, nonselective cation channels within the plasma membrane of diverse cells, including neurons, cardiomyocytes, and immune cells[1][2][4][5]. TRPC3 plays a crucial role in mediating store-operated calcium entry (SOCE) and contributes to cellular calcium homeostasis, which is vital for many physiological processes such as neurotransmitter release, muscle contraction, hormone secretion, and immune cell activation[1][2][4]. The channel can be activated by second messengers like diacylglycerol (DAG), and is functionally regulated via interactions with calmodulin, the IP3 receptor, and intracellular calcium levels[2]. Dysfunction or dysregulation of TRPC3 has been implicated in a range of disorders, including neurodegenerative diseases, cardiac hypertrophy, hypertension, and abnormalities in immune cell signaling[1][2][4]. Pharmacological modulation of TRPC3, for example by agonists like GSK-1702934A, is a focus of research for therapeutic intervention, although no approved drugs are currently available[2]. The channel's structure includes features characteristic of TRP channels (e.g., ankyrin repeats, transmembrane helices, TRP helix), and recent structural insights suggest unique gating and lipid-sensing mechanisms distinguishing it from other family members[1][2].
Modulation of channel gating (by direct binding or allosteric mechanisms); Allosteric modulation through cytosolic protein interactions (e.g., calmodulin/IP3 receptor); Lipid (diacylglycerol)-induced channel activation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Canonical transient receptor potential channel 3 (TRPC3).